A new non-opioid medicine for opioid use disorder
Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder
This research explores a new non-opioid medicine, C4X3256, to help people overcome opioid use disorder.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indivior, INC. NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-11090515 on NIH RePORTER |
What this research studies
Opioid use disorder is a serious health challenge, and while existing medicines help, they often have limitations like abuse potential or requiring abstinence before starting. Current treatments primarily target the mu-opioid receptor, which can lead to concerns about misuse and access restrictions. This new medicine, C4X3256, works differently by targeting the orexin-1 receptor, offering a non-opioid approach. We hope this new mechanism can provide a safer and more accessible option for those struggling with opioid addiction.
Who could benefit from this research
Good fit: Ideal candidates would be individuals diagnosed with opioid use disorder who are seeking new treatment options, especially those who have faced challenges with current opioid-receptor-targeting medications.
Not a fit: Patients who are not seeking treatment for opioid use disorder or for whom existing treatments are already effective may not receive additional benefit from this particular approach.
Why it matters
Potential benefit: If successful, this new non-opioid medicine could provide a safer and more accessible treatment option for individuals with opioid use disorder, potentially reducing misuse and barriers to care.
How similar studies have performed: This approach is novel as it targets a different pathway (Orexin-1 receptor) compared to existing opioid use disorder medications that primarily target the mu-opioid receptor.
Where this research is happening
Richmond, United States
- Indivior, INC. — Richmond, United States (Active)
Researchers
- Principal investigator: Heidbreder, Christian Arthur — Indivior, INC.
- Study coordinator: Heidbreder, Christian Arthur
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.